VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (4560)	4/6/1998 11:51:00 AM
From: Russian Bear	Read Replies (3) of 9719

A question for any and all: Does anyone have any thoughts on the Cephalon (myotrophin) FDA advisory panel meeting cancellation? biz.yahoo.com I am puzzled by the purported reason behind the cancellation: ostensively, to allow the FDA to continue its review of the myotrophin NDA. My "gut feeling" is that this is not that bad a thing (after all, they could easily have held the meeting on Thursday, as planned, and recommended against approval. That would have been far worse, No?) I know that many of us (but, alas, not I) are quite good at reading between the FDA's lines. What do you think? BTW, I have no position in CEPH or CQE, but I am giving the prospect serious consideration. Thanks, RB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next